NEW YORK (GenomeWeb News) – ExonHit Therapeutics today said that it has licensed from Institut Gustave Roussy exclusive, worldwide rights to a tissue-based breast cancer signature that will developed into an assay.
Paris-based ExonHit plans to validate IGR's signature in a larger population and will have access to samples from IGR's biobank. The firm intends to launch a research-use-only test within 12 months. Following further validation, it intends to launch a clinical diagnostic assay based on the signature.
IGR recently published in Lancet oncology a paper regarding the breast cancer signature, which it said has an accuracy of better than 95 percent. The marker was studied using ExonHit's SpliceArray platform. According to ExonHit, the signature allows for discrimination between malignant tumors and benign lesions from cells sampled through fine-needle aspiration.
Loic Maurel, president of the Management Board of ExonHit, said that the licensing of the new signature "is in line with our strategy to reinforce our diagnostic portfolio with simple, accurate and patient-friendly tests. As our first non blood-based diagnostic, this is a different and complementary approach to our ongoing cancer diagnostic programs with bioMerieux."
In exchange for the exclusive, worldwide patent rights, ExonHit will provide IGR with an upfront payment, development milestones, and royalties on future sales. Financial terms were not disclosed.